drugset
drugset / Trial / NCT01497119

A Study of JNJ-39758979 in Adult Japanese Patients With Moderate Atopic Dermatitis

NCT01497119 ↗

Phase 2 Terminated 88 enrolled Janssen Pharmaceutical K.K.
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the safety, tolerability, and efficacy of JNJ-39758979 in adult Japanese patients with moderate, active atopic dermatitis.

Timeline

Start
2011-10
Primary completion
2012-02
Completion
2012-02

Drugs

EvaluationDrugModalityDoseRoute
Subject JNJ-39758979 Small molecule 100 mg Oral
Subject JNJ-39758979 Small molecule 300 mg Oral

Indications

atopic eczema